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Abstract:  Aged dogs and humans share complex cognitive and pathological responses to aging. Specifically, dogs   
develop Alzheimer’s Disease (AD) like beta-amyloid (A) that are associated with cognitive deficits. Currently, therapeutic 
approaches to prevent AD are targeted towards reduced production, aggregation and increased clearance of A. The  
current review discusses cognition and neuropathology of the aging canine model and how it has and continues to be  
useful in further understanding the safety and efficacy of potential AD prevention therapies targeting A. 
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INTRODUCTION 
  Alzheimer’s disease (AD) is the most common cause of 
dementia in the elderly and currently affects 5.5 million peo-
ple in the United States alone. AD is characterized by the 
presence of senile plaques and neurofibrillary tangles (NFTs) 
in the brain [1-3]. Given that the greatest risk factor for de-
veloping AD is age and that our elderly population is rapidly 
rising, it is critical to identify preventative measures and 
early interventions to slow or stop the disease [4]. The   
current review provides an overview of how the dog model 
of human aging and AD has been and continues to be a   
beneficial preclinical model to test the efficacy and safety of 
certain types of disease modifying treatments for AD. 
Beta-Amyloid (A) 
  Senile plaques, which are primarily composed of -
amyloid (A), are one of two neuropathological characteris-
tics of AD [5]. The A peptide is produced by the sequential 
cleavage of the amyloid precursor protein (APP) by - and - 
secretases [6, 7]. Cleavage by -secretase results in differing 
lengths of A, with the 42 amino acid form, A42, making up 
most of the insoluble deposits found in the AD brain [8]. A 
is largely thought to play a role in the disease process   
because it is a unifying pathological feature of the genetically 
diverse forms of AD. 
  The gene encoding APP is located on chromosome 21. 
Because three copies of this chromosome are present in   
individuals with Down Syndrome (DS), DS research has 
been particularly important in elucidating the role of A in 
AD [9, 10]. Individuals with DS show A deposition as early  
as 8 years of age [11] and have classical neuropathological 
features of AD by their early forties [12-15]. The localization 
of the APP gene to chromosome 21 initiated a search for  
genetic linkages in families with autosomal dominant AD [7],  
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leading to the association of missense mutations in the APP 
gene with familial AD [16-19]. Furthermore, duplication of 
the APP gene causes autosomal dominant AD in the absence 
of DS [20]. Past studies of DS and familial AD have   
established that A is a pathological feature of both disorders 
and that A production and decreased clearance [21, 22] is  
at the root of disease progression. The importance of A in 
the pathogenesis of AD has led to the search for therapeutic 
interventions targeting A. 
Animal Models for A Therapeutics: Beyond the Mouse 
  Potential AD therapeutics are generally screened first   
in transgenic mouse models of AD. As well as being   
inexpensive and easy to house, mouse models are ideal be-
cause they age quickly and their entire genome is mapped. 
However, mice do not produce human sequence A naturally 
[23]. Transgenic mouse models of AD are produced by over 
expressing mutant human APP alone or combined with 
transgenic presenilin 1 (PS1) and presenilin2 (PS2) genes in 
mice, which leads to A plaque formation [24]. Importantly, 
unlike humans, transgenic mice show cellular and behavioral 
resilience to A pathology and thus do not develop the   
extensive neuronal loss observed in the AD brain. While 
transgenic mouse models continue to get more complex and 
more closely replicate human AD pathology, there are   
several components of the disease process that mice cannot 
model. For example, most AD patients neither have the   
genetic mutations present in transgenic mice nor overexpress 
these mutations if present at such high levels. While   
transgenic mouse models have been and will continue to be 
instrumental in the development of therapeutics, the basic 
evolutionary differences between the two species makes taking 
potential therapeutics from mice to humans less direct. 
  The successful development of therapeutic interventions 
targeting A benefits from testing in animal models that 
naturally recapitulate critical aspects of human disease.   
Diseases associated with brain aging are especially challenging, 
due to the time required to track both the aging process and 
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animal model has several key features in addition to the 
natural development of AD pathology. For example, it   
is beneficial for an animal model of AD to have a naturally 
diverse response to aging, given that humans show individual 
variations with age [25-27]. While some people show mild 
cognitive decline with age, others develop severe cognitive 
decline. Still others develop no visible signs of decline, the 
definition of “successful aging”. This spectrum of cognition 
in aging is suggested to result from both genetic and   
environmental factors [28, 29], another key feature of an 
ideal animal model of AD. Although increased variability 
presents statistical challenges, requiring additional animals 
and experimental studies, natural diversity offers certain 
unique advantages. The ability to compare similarly aged 
animals with differing cognitive functions allows researchers 
to distinguish pathological underpinnings associated with 
cognitive function. 
  Not all cognitive domains are equally vulnerable to aging 
or AD in humans. For example, the first sign of AD in   
humans, often referred to as amnestic mild cognitive   
impairment (MCI), is defined by a gradual decline in   
episodic memory function with preserved general cognitive 
and functional abilities, combined with no evidence of   
dementia [27, 30]. As the disease progresses into clinical AD, 
patients show a disturbance in at least one of the following 
cognitive functions: language, motor skills, visual processing 
or executive function [31]. More specifically, AD patients 
show a decline in declarative learning, while procedural 
abilities remain intact. Animal models that capture these 
cognitive characteristics are well suited to develop and test 
therapeutic interventions to translate into human clinical 
trials in AD patients. Unfortunately, no single animal model 
can replicate all aspects of AD, but each can provide unique 
strengths that advance our knowledge.  
CANINE MODEL OF AGING 
  The canine model has a rich literature in psychological 
and neurobiological research, dating back to the 1800s.   
Canines are useful for aging research, have moderate 
lifespans of 12 to 20 years, depending on the breed [32, 33], 
and are easy to handle due to a long history of domestication 
[34]. Furthermore, canines are highly motivated to perform 
consistently on cognitive tests using simple food rewards, 
making food deprivation paradigms unnecessary. In contrast, 
mice are not readily cooperative in performing behavioral 
tasks, so physiological stressors including food restriction, 
water deprivation and immersion in water are often used 
[35]. Therefore measures of cognition may be engaging   
other processes involved in stress response, confounding 
performance scores. Importantly, the cognitive decline and 
progressive age-associated neuropathology observed in dogs 
parallels that of humans. 
Cognition and Aging in Dogs 
  Cognitive testing procedures for canines were initially 
developed by modifying non-human primate cognitive tests 
[36]. A variety of tests have been developed to assess   
cognitive function in various domains and corresponding 
brain localization in dogs. Table 1 [originally published in 
37] outlines cognitive domains assessed in dog aging and 
how they compare with assessment tasks for non-human 
primate and humans. Many of these tests are analogous to 
cognitive tests used for nonhuman primates and humans. As 
in humans, canine individual variability and domain-specific 
cognitive vulnerabilities are key features of decline with age 
[36]. Beginning in middle age, individual variability in cog-
nitive scores begins to increase, with the largest variability 
seen in aged dogs [38]. Additionally, vulnerability to decline 
with age varies as a function of cognitive domain and the 
cortical circuits engaged. For example, size discrimination 
learning is sensitive to age, while simple object discrimination 
is not [36, 38, 39], similar to monkey models of aging   
[40-44]. Further, prefrontal dependent reversal learning is 
more age sensitive than discrimination learning [36, 38, 39]. 
  Efficacy of a therapeutic intervention for AD is   
ultimately measured by its ability to stabilize or improve 
function in cognitive domains compromised by AD. The 
canine parallels features of human cognitive decline and has 
well established measures that are domain specific [reviewed 
in 37]. Use of the canine model allows researchers to study 
the complex cognitive implications of therapeutic inter- 
ventions, an important measure preceding clinical trials. 
Neuropathology in Aging Dogs 
  In addition to the cognitive features of aging, dogs natu-
rally develop brain changes similar to human brain aging 
[reviewed in 37]. Importantly, a key feature that makes dogs 
useful as a model of human A pathogenesis was the obser-
vation in 1956, by Braumühl, who reported “Alzheimer’s-
like” senile plaques in aged dogs [reviewed by 34]. Dogs 
initially develop plaques between the ages of 8 and 9 years 
[37, 45], a relatively young age, compared to many non-
human primate models with naturally occurring AD-like 
pathology [46, 47]. Deposition of human-like A accumula-
tion in the aged canine brain has been well-described [34, 
48-52]. There are significant homologies between canines 
and humans in the APP protein sequence, as well as in many 
enzymes involved in the processing of APP to form A 
(http://www.ensembl.org/Canis_familiaris/).  
  Diffuse plaques are the predominant subtype of A in the 
canine model [49, 52-56], whereas more compact neuritic 
plaques (i.e. A associated with tau positive neurites) are 
predominant in AD Fig. (1A,  B). However, evidence sug-
gests that diffuse plaques are extensive in humans and appear 
early in AD progression [57, 58]. As observed in humans, 
A pathology in canines shows specific brain regions being 
differentially vulnerable to A [1, 2, 50, 52, 59-61]. Modeling 
early stages of AD is critical, given that AD therapies are 
likely to be most effective early in disease progression.   
Importantly, unlike humans, canines do not develop NFTs 
[47, 53, 55, 56], the second neuropathological characteristic 
of AD. However, the lack of NFTs in canines is a feature  
of the model that can be used to differentiate between the 
effects of A and NFTs in the disease process, an ongoing 
subject of AD research. 
  Both humans and canines develop cerebrovascular   
amyloid angiopathy (CAA), the deposition of A in association 
with the cerebrovasculature Fig. (1C, D). The presence of CAA 
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and testing therapeutic interventions to target A. In both 
canines and humans with CAA, the blood vessels of the 
brain typically contain the shorter, 40 amino acid-long   
species of A [62-64]. Further, the distribution of CAA   
is similar in both species, with the occipital cortex being 
predominantly susceptible. Vascular A may compromise 
the blood-brain barrier, disrupt vessel wall viability [65] and 
cause microhemorrhages [66, 67]. 
  Recently, the focus in AD pathogenesis has shifted   
from A plaques to consider smaller, soluble forms of A 
assemblies called A oligomers. Oligomers are highly toxic 
and impair synaptic function [68]. Furthermore, elevated 
oligomer levels are strongly associated with cognitive   
dysfunction [69, 70]. A recent study by Pop et al., examined the 
accumulation of oligomeric A in the temporal lobe of canines. 
These results provide evidence that canines, like humans, 
experience an increase in toxic oligomers with age [71]. 
  Another key feature of AD that is also found in dogs is 
neuronal loss in the presence of cognitive deficits. A study 
by Pugliese et al., (2007) demonstrated that cognitive deficits 
correlated with loss of purkinje cells [72]. More recently, a 
study by Insua et al., (2010) examined neuroadrenergic   
neurons in the locus ceruleus of aged canines, a group of 
neurons that are vulnerable to AD in humans [73, 74]. They 
found that cognitively impaired dogs exhibited significant 













Fig. (1). Immunoreactivity for A 1-42 in frontal cortex brain tissue 
of (A) an aged canine and (B) an aged human. Compact A deposits 
are similar in humans and canines (arrow head). The outline of   
an intact neuron enveloped by a diffuse plaque is visible (arrow). A 
1-40 immunoreactivity of cerebral amyloid angiopathy is similar in 
aged canine occipital cortex (C) and aged human occipital cortex (D). 
 
  The efficacy of A modifying therapies are measured by 
neuropathological and cognitive improvement. Studies have 
Table 1.  Cognitive Domains Assessed in Dog Aging and Comparison with Nonhuman Primate Tasks and Analogous Tasks Used in 




Localization in  
Dog Brain 
Nonhuman Primate Tasks 
Examples of Human  
Neuropsychological Tasks** 
Visual discrimination learning  Medial temporal lobe/parietal lobe*  Visual discrimination learning [40, 164] 
Learning 
Reward and object approach 
learning 
Nigrostriatal and motor cortex* 
Food pickup task, fine motor learning 
[168, 169] 
digit copy, rotary pursuit, face 
discrimination [165], object 
discrimination [166, 167] 
delayed nonmatching to 
sample acquisition 
Rhinal cortex [170]  Object recognition memory task [171] 
delayed nonmatching to 
sample memory 
Rhinal cortex [170]  Object recognition memory task [171] 
spatial delayed nonmatch to 
sample acquisition 
Dorsolateral prefrontal cortex [170]  Delayed Response Task [43, 173] 
Memory 
spatial delayed nonmatch to 
sample memory 
Hippocampus [174]  Delayed Response Task [43, 173] 
Delayed recognition and 
recall, digit span [172] 
Visual reversal learning  Prefrontal cortex/medial temporal lobe [175]  Visual reversal learning [40, 164] 
Oddity discrimination  Prefrontal cortex/medial temporal lobe*  N/A 
Egocentric spatial reversal 
learning 
Hippocampal/prefrontal cortex*  Spatial reversal [164] 
Executive 
Function 
Size concept learning  Prefrontal cortex/medial temporal lobe*  Hierarchical/Relational learning [177] 
card or object sorting tasks, 
set shifting, response inhibi-
tion [176] 
Landmark discrimination  Prefrontal cortex/parietal cortex*  Landmark discrimination [178] 
Visuospatial 
Function  Egocentric spatial learning  Hippocampus/medial temporal lobe*  Spatial learning [164] 
Visual construction, block 
design, spatial learning [166, 
167] 
* Proposed localization – not confirmed in lesion studies in dogs 
** Neuropsychological tasks for humans that assess function in similar cognitive domains.  654    Current Neuropharmacology, 2011, Vol. 9, No. 4  Martin et al. 
found an association between A load and cognitive   
dysfunction in aging dogs, similar to humans with AD [48]. 
As with humans, there is not a perfect link between the   
extent of A pathology and the severity of cognitive decline, 
suggesting that other neuropathological cascades are involved 
in neurodegeneration. The natural presence of cognitive   
decline and A neuropathology make the dog a valuable 
model in developing therapeutics for AD.  
POTENTIAL TARGETS FOR A MODIFICATION 
 A  deposition is thought to result from one or more of 
the following mechanisms: 1) increased production of A, 2) 
decreased A clearance and/or 3) enhanced aggregation of 
A Fig. (2). Strategies to decrease A deposition have   
focused on modulating all of these mechanisms individually. 
For example, studies focused on preventing A production 
inhibit the enzymatic step required to cleave APP into an A 
peptide. However, the monomeric A peptide alone is easily 
cleared from the brain via the blood-brain barrier and is not 
considered a toxic form of A [76]. The A peptide becomes 
more toxic as it aggregates to the oligomer structural state 
[77-81] and subsequently further assembles into insoluble 
fibrils [reviewed in 82]. Therefore, a considerable amount of 
research is also focused on therapeutic interventions that 
prevent A aggregation or enhance clearance of A and A 
aggregates. Here we will review some promising therapies 
that target production (antioxidant diet, behavioral enrich-
ment, BACE1 inhibition, statins), aggregation (metal chela-
tors) and clearance (A immunotherapy) of A Fig. (2). The 
dog model has been or may be useful for determining the 
efficacy of each potential therapy. 
Antioxidants, Behavioral Enrichment and Prevention of 
A Deposition 
  Lifestyle factors are poorly understood, yet are potentially 
effective at preventing A production. Specifically, nutrition 
and lifestyle enrichment (e.g. exercise, education and   
social interaction) effectively prevent cognitive decline   
and A production [83]. Results from mouse models of   
AD suggest that an antioxidant enriched diet [84, 85] and/or 
environmental enrichment [86] decreases production of A 
peptides. Human studies have determined that nutrition and 
other lifestyle factors offer cognitive benefits and reduce the 
risk of developing AD [87-93]. However, the genetic and 
environmental variability of the human population makes it 
difficult to determine the efficacy of these complex inter- 
ventions and their mechanisms of action.  
  To measure cognitive and neurobiological benefits of 
lifestyle factors in aged dogs, diet and environment have 
been evaluated singularly and in combination, using a variety 
of learning and memory tasks. In the first study, aged   
beagles were treated with either a standard senior dog diet or 
an antioxidant-rich senior dog diet for 6 months [88, 94]. 
The formulation differences between control and enriched 
diets were as follows: D,L-alpha-tocopherol acetate (120 
ppm vs. 1050 ppm), L-carnitine (<20ppm vs. 260ppm), D,L-
alpha-lipoic acid (<20ppm vs. 128ppm), ascorbic acid as 
Stay-C (<30ppm vs. 80ppm) and 1% inclusion of each of the 
following (1 to 1 exchange for corn): spinach flakes, tomato 
pomace, grape pomace, carrot granules and citrus pulp.   
Oddity discrimination learning was assessed after 6 months 
of treatment. Aged dogs fed an antioxidant-enriched diet had 
significantly less age-dependent cognitive impairment than 
aged dogs fed the control diet.  
  In the follow up study, cognitive benefits of the antioxi-
dant diet were evaluated after two years of treatment in the 
aged dogs [95]. The antioxidant-enriched diet was as   
described above. Further, the cognitive effects of the anti- 
oxidant diet either alone or in combination with behavioral 
enrichment were measured. Behavioral enrichment consisted 
of group exercise for 15 minute intervals twice a week,   
exposure to toys that were alternated weekly and housing 
with kennel mates. After two years of treatment, results   
suggested an attenuation of age-related cognitive decline   









Fig. (2). A-modifying therapies can target the modulation of production and clearance. 1) Lifestyle interventions (e.g. nutrition and lifestyle 
enrichment) increase -secretase activity. -secretase cleaves APP in the middle of the A region (denoted in yellow), releasing a non-
amyloidogenic, soluble peptide. 2) BACE inhibitors and statins decrease -secretase activity or BACE1 protein levels, which may result in 
decreased production of A from APP. 3) Metal chelators prevent metal ions from inducing A aggregation, thereby allowing A peptides to 
be cleared from the brain. 4) Immunization therapies use anti-amyloid antibodies to bind and remove A deposits. Therapeutic Interventions Targeting Beta Amyloid Pathogenesis  Current Neuropharmacology, 2011, Vol. 9, No. 4    655 
behavioral and antioxidant enrichment. At the end of the 
study, A neuropathology was measured in the prefrontal 
cortex and the extent of A was significantly decreased in 
animals receiving the antioxidant enrichment [96]. Further, 
A pathology was most robustly decreased in animals   
that received both antioxidant and behavioral enrichment, 
suggesting that the combination of treatments may affect   
the production and/or clearance of A. An increase in   
alpha-secretase enzyme activity in aged dogs treated with the 
antioxidant and behavioral enrichment protocols, suggests a 
shift towards non-amyloidogenic APP processing. These 
canine studies provide support for the combination of anti-
oxidant and behavioral enrichment during the aging process 
in order to maintain cognition and inhibit A production. 
Further, these results emphasize the importance of therapeutic 
interventions that target -secretase activity. The canine model 
has lead to an increased understanding of the mechanisms and 
efficacy of these interventions on cognition and pathology. 
BACE1 Inhibition and Prevention of A Production 
  Two sequential enzymatic cleavages of APP are neces-
sary to produce A. The first is cleavage of APP by -
secretase APP-cleaving enzyme 1 (BACE1). BACE1 cleaves 
APP, generating the N-terminus of A. In AD brains, levels 
of BACE1 protein and activity are approximately twice that 
of controls [97-99], indicating enhanced production of A. 
BACE1 is a promising target for the development of thera-
peutic interventions to lower A production. However, it is 
important to note that BACE1 has substrates other than APP 
[100] and toxic side effects could result when BACE1 is 
fully inhibited. One possible side effect identified in a BACE1 
knockout mouse (BACE1
-/-) involved NRG1, a substrate for 
BACE1 and a protein implicated in schizophrenia [101]. 
BACE1
-/-mice exhibit endophenotypes typically seen in 
schizophrenia [101, 102], leading researchers to test whether 
partial BACE1 inhibition decreases A load while limiting 
unwanted side effects. Using a heterozygous mouse 
(BACE1
+/-) to impart partial BACE1 inhibition, McConlogue 
et al., found decreased A burden in 13 and 18 month   
old  BACE1
+/-APP transgenic mice [103]. Thus, BACE1   
inhibition remains a potential therapeutic target. 
  The use of mouse models in designing BACE1 inhibitors 
has been instrumental. When inhibiting an enzyme that   
plays critical physiological roles in brain chemistry, it is   
increasingly important to test the putative therapy in several 
different models of AD prior to clinical trial. Humans and 
canines share a 98% homology in BACE1 (http://www. 
ensembl.org/Canis_familiaris/). Prior to clinical trials, testing 
therapeutic interventions that target BACE1 inhibition in a 
dog model may provide additional information regarding the 
dose requirements, safety and efficacy of these AD therapies. 
Statins, Cholesterol and the Prevention of A Production 
  Several cross-sectional or case-control epidemiological 
studies have revealed a striking link between cholesterol-
lowering drugs (e.g. statins and others) and a 20-70%   
reduction in risk of developing AD [104-111]. However 
some [112-114], but not all [115], prospective studies have 
reported no link between statin use and protection against 
dementia. Differential reports of the positive effects of   
statins on the development of AD may be due to the cohort 
studied, confounds by indication, type of statin used,   
age group studied, and type of study conducted (e.g. cross-
sectional, case-control or prospective study) [116, 117].   
Further, in preliminary AD clinical trials with simvastatin 
[118] and atorvastatin [119-122], modest cognitive benefits 
have been reported. In particular, AD patients with mild   
to moderate dementia who were treated with 80 mg/day 
atorvastatin had significantly improved scores on one meas-
ure of cognition (ADAS-Cog) at 6 months of treatment, with 
smaller non-significant benefits at 12 months [120].  
  Recent studies strongly suggest once the signs of AD are 
evident that the use of statins might reflect a preventative 
approach rather than a treatment. For example, several   
studies suggest that mid-life cholesterol levels and statin   
use impact the risk of developing AD [123, 124]. Further,  
in a 5-year prospective study of individuals who were   
not demented at the start of the trial, statin use resulted in  
a 50% reduction in the risk of developing either dementia  
or cognitive impairments without dementia (CIND), as   
compared to placebo/control [125]. Thus, modulating   
mid-life cholesterol and/or statin administration and/or   
implementing statin use prior to CIND or dementia may be 
more beneficial than treatment approaches in patients with 
AD. Prevention studies are long, costly and challenging   
to conduct, but can be greatly facilitated by appropriate   
preclinical testing. Studies in animal models can provide 
preliminary information regarding potential benefits of statins 
in the prevention of cognitive decline and AD neuropathology. 
  Statins may reduce the risk of incident AD through the 
prevention of A production [126, 127]. In rodent models, 
treatment with inhibitors of 3-hydroxy-3-methylglutaryl   
coenzyme A (HMG-CoA) or statins reduces A [128].   
However, rodents respond to statin treatment by massively 
upregulating HMG-CoA reductase levels [129-132].   
To compensate, long-term studies in rodent often employ 
physiologically excessive doses, making it difficult to   
translate the results of these studies into human trials.  
  In contrast to rodent models, the dog model is a useful 
model for studies of chronic statin treatment, given similari-
ties with humans in terms of dose requirements, responsive-
ness, drug handling and metabolism [129, 133]. For example, 
in a study of 12 animals, dogs were treated with 80 mg/day 
of atorvastatin for 14.5 months (Head, unpublished data). 
Peripheral levels of cholesterol, low density lipoproteins, 
triglycerides and high density lipoproteins were reduced in 
treated dogs. Surprisingly, a transient impairment in reversal 
learning was observed, suggesting prefrontal dysfunction. 
Spatial memory remained unchanged up to over a year of 
treatment. The lack of cognitive benefits of treatment was 
also reflected by a lack of reduction in plasma, cerebrospinal 
fluid and brain A. Interestingly, BACE1 protein level was 
decreased in the brains of atorvastatin-treated dogs. This 
intriguing outcome may suggest that statins might be more 
useful to prevent the production of A through lowering 
BACE1 if started in animals in middle age, consistent with 
human studies indicating that middle-aged individuals using 
statins are protected from AD. Aged dogs are a unique model 
that may provide novel insights and translational data to   
predict outcomes of statin use in human clinical trials. 656    Current Neuropharmacology, 2011, Vol. 9, No. 4  Martin et al. 
Metal Chelators and Reducing A Aggregation 
 Preventing  A aggregation may also be a promising   
approach to AD prevention. Metal ions such as zinc (Zn
2+), 
Copper (Cu
2+) and iron (Fe




2+ abnormally accumulate 
in the brains of AD patients [138]. Accumulation of these 
metals increases with disease progression, and high levels are 
found in A plaques [139]. Additionally, studies suggest that 
the presence of Cu
2+ is required for beta-amyloid aggregation 
and neurotoxicity [140]. A promising therapeutic approach to 
AD prevention involves the administration of agents to chelate 
metal ions and remove them from the blood and brain, which 
may result in A disaggregation and clearance. For example, 
in a study of transgenic AD mice (Tg2576), the Cu
2+ and 
Zn
2+chelator clioquinol reduced metal ion accumulation in   
the brain, reduced A burden by 49% [141] and improved 
cognitive performance [142]. The use of clioquinol as a   
treatment for AD has gone to phase II clinical trials [143], 
with inconclusive results [144, 145]. Following clioquinol 
administration, patients with mild AD had decreased plasma 
A42 with no cognitive benefit, while patients with severe   
AD showed cognitive benefit with no decrease in plasma 
A42. Questions of efficacy and safety remain unanswered, in 
part due to the small sample size and incomplete understanding 
of the mechanism of clioquinol in decreasing A. 
  Metal ion chelators have potential in AD therapy,   
but remain controversial. Manipulating essential metals   
in the CNS can have neurotoxic effects and it is important  
to examine the efficacy and pathological mechanism of a 
potential therapy in more than one animal model prior to 
clinical trials. Additionally, it is important to test chelation 
therapies in an animal model that naturally exhibits A  
pathology, A associated cognitive decline and metal   
dyshomeostasis with age, in order to offer insight into   
the mechanisms, efficacy and safety of these interventions. 
Importantly, dogs exhibit these characteristics and have   
increased metal ions in the brain with age [146]. 
A Vaccination and Increased Clearance of A 
  As mentioned previously, another approach to reducing 
A and potential effects on cognition is to clear pre-existing 
or new deposits. In transgenic mouse models of AD,   
deposition of A was prevented or significantly reduced by 
vaccination with fibrillar A1-42 [147-150]. In parallel with 
A reduction, learning and memory was improved by either 
active [148, 149, 151] or passive immunization [152-155].  
  Aged dogs may be very useful for assessing A-targeted 
immunization therapies. Using an active immunization   
approach, dogs were injected with fibrillar A1-42 formulated 
with aluminum hydroxide, an adjuvant safe for use in   
humans [156]. Over a 2 year period of monthly vaccinations, 
surprisingly little cognitive improvement was observed on 
multiple measures of learning and memory, using tasks   
that are both age and intervention-sensitive. Interestingly, 
after 22 months of treatment, a significant improvement on 
reversal learning in treated animals was observed. Overall, 
error scores in control dogs increased over time, reflecting 
both an increase in task difficulty and the aging process. 
However, error scores were differentially affected by treat-
ment, given that animals immunized with fibrillar A 
showed maintenance of reversal learning ability over time, 
suggesting maintained frontal lobe function. These results 
suggest that immunization with fibrillar A1-42 leads to   
improved and maintained executive function in aged   
dogs, when both pre-existing A and cognitive deficits   
are typically present.  At the end of the study, A plaque   
accumulation, soluble and insoluble A1-40 and A1-42 were 
measured. Reductions in A were observed in multiple brain 
regions that are essential for learning and memory, including 
the prefrontal, parietal, occipital and entorhinal cortex.  
  Studies in higher mammalian species with disease char-
acteristics that naturally parallel those in human AD may be 
a critically important step in the process of determining 
whether a drug should be taken to a clinical trial. For   
example, the promise of A vaccination was derived from 
research in the transgenic mouse models of AD and rapidly 
translated into a human clinical trial. However, the clinical trial 
in patients with AD using a similar formulation of immunizing 
with fibrillar A1-42 (AN1792 study) lead to an unexpected 
adverse event and an early halt to the study [157], which was 
not predicted from the mouse studies. Further, the clinical 
outcomes were not as robust as observed in transgenic mice. 
In the Swiss cohort of the trial, function was maintained on a 
global test of cognition (Mini-Mental State Examination) and 
on a hippocampal-dependent task (visual paired associated 
test) in vaccinated individuals who developed antibodies 
capable of binding to plaques [158]. However, in a second, 
larger study and in contrast to the predicted outcomes based 
on work in transgenic mice, no differences were observed  
on several cognitive and disability scales between treated 
and untreated patients [159]. One promising outcome was 
that 12 months after treatment, the composite score from a 
battery of neuropsychological tests indicated less severe 
memory decline [159]. Eight patients enrolled in the 
AN1792 study have been autopsied and show A plaque 
reduction without any effect on the extent of NFTs or CAA 
[160-162]. Interestingly, in a case report by Masliah et al., 
(2005), the frontal cortex showed the largest response to 
immunotherapy [162]. Notably, the decreased A pathology 
persisted 5 years after the last vaccination [163], although 
reduced brain A did not slow AD progression and 7 these 
patients had severe end stage dementia prior to death. These 
findings parallel observations in the dog vaccination study, 
further emphasizing the need to test therapeutics in natural 
models of aging and AD.  
  Although there were several important differences be-
tween the dog and human vaccination studies [reviewed in 
156]), dog studies suggest that reducing plaque accumulation 
or total A in dogs with pre-existing pathology may be insuf-
ficient to restore neuronal function without directly targeting 
neuron health. Evidence from the previously discussed anti-
oxidant and behavior enrichment study suggest alternative 
pathways that might be used in combination with A  
vaccination to improve neuronal health. For example,   
significant improvements in cognition may be achieved   
by combining A immunotherapy with either behavioral 
enrichment or an antioxidant diet to restore neuron health 
after A removal. Therapeutic Interventions Targeting Beta Amyloid Pathogenesis  Current Neuropharmacology, 2011, Vol. 9, No. 4    657 
SUMMARY 
  AD is a complex disease that remains a challenge in 
terms of developing therapeutics for clinical trials. To date, 
no disease pathology modifying therapies are commercially 
available for AD. Although mice and other rodent models 
are invaluable in learning about the mechanistic pathways 
involved in AD pathogenesis and identifying therapeutic 
targets, these studies should be extended to natural models to 
design safe and effective therapeutic strategies. 
  Because AD affects multiple pathways, therapeutic 
strategies may need to target the disease using parallel   
approaches. As discussed above, this can be achieved by 
combining therapeutics. For example, it may be beneficial to 
pair therapies that increase A clearance with those that repair 
neuron health and attenuate oxidative stress. The canine model 
complements other animal models of AD and continues to be 
a beneficial system in which to test the efficacy and safety of 
therapeutics or preventative approaches for AD. 
ACKNOWLEDGEMENTS 
  Funding provided by NIH/NIA AG031764 and AG032550. 
REFERENCES 
[1]  Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-
related changes. Acta Neuropathol., 1991, 82(4), 239-259. 
[2]  Braak, H.; Braak, E.; Bohl, J. Staging of Alzheimer-related cortical 
destruction. Eur. Neurol., 1993, 33(6), 403-408. 
[3]  Khachaturian, Z.S. Diagnosis of Alzheimer's disease. Arch. 
Neurol., 1985, 42(11), 1097-1105. 
[4]  Evans, D.A.; Funkenstein, H.H.; Albert, M.S.; Scherr, P.A.; Cook, 
N.R.; Chown, M.J.; Hebert, L.E.; Hennekens, C.H.; Taylor, J.O. 
Prevalence of Alzheimer's disease in a community population of 
older persons. Higher than previously reported. JAMA,  1989, 
262(18), 2551-2556. 
[5]  Mirra, S.S.; Heyman, A.; McKeel, D.; Sumi, S.M.; Crain, B.J.; 
Brownlee, L.M.; Vogel, F.S.; Hughes, J.P.; van Belle, G.; Berg, L. 
The Consortium to Establish a Registry for Alzheimer's Disease 
(CERAD). Part II. Standardization of the neuropathologic 
assessment of Alzheimer's disease. Neurology,  1991, 41(4),  
479-486. 
[6]  Murphy, M.P.; LeVine, H., 3rd. Alzheimer's disease and the 
amyloid-beta peptide. J. Alzheimers Dis., 2010, 19(1), 311-323. 
[7]  Selkoe, D.J. Amyloid beta-protein and the genetics of Alzheimer's 
disease. J. Biol. Chem., 1996, 271(31), 18295-18298. 
[8]  Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. 
Physiol. Rev., 2001, 81(2), 741-766. 
[9]  Antonarakis, S.E.; Lyle, R.; Dermitzakis, E.T.; Reymond, A.; 
Deutsch, S. Chromosome 21 and down syndrome: from genomics 
to pathophysiology. Nat. Rev. Genet., 2004, 5(10), 725-738. 
[10]  Lott, I.T.; Head, E.; Doran, E.; Busciglio, J. Beta-amyloid, 
oxidative stress and down syndrome. Curr. Alzheimer Res., 2006, 
3(5), 521-528. 
[11]  Leverenz, J.B.; Raskind, M.A. Early amyloid deposition in the 
medial temporal lobe of young Down syndrome patients: a regional 
quantitative analysis. Exp. Neurol., 1998, 150(2), 296-304. 
[12]  Giaccone, G.; Tagliavini, F.; Linoli, G.; Bouras, C.; Frigerio, L.; 
Frangione, B.; Bugiani, O. Down patients: extracellular preamyloid 
deposits precede neuritic degeneration and senile plaques. 
Neurosci. Lett., 1989, 97(1-2), 232-238. 
[13]  Mann, D.M. Cerebral amyloidosis, ageing and Alzheimer's disease; 
a contribution from studies on Down's syndrome. Neurobiol. 
Aging, 1989, 10(5), 397-399; discussion 412-394. 
[14]  Iwatsubo, T.; Mann, D.M.; Odaka, A.; Suzuki, N.; Ihara, Y. 
Amyloid beta protein (A beta) deposition: A beta 42(43)   
precedes A beta 40 in Down syndrome. Ann. Neurol., 1995, 37(3), 
294-299. 
[15]  Lemere, C.A.; Blusztajn, J.K.; Yamaguchi, H.; Wisniewski, T.; 
Saido, T.C.; Selkoe, D.J. Sequence of deposition of heterogeneous 
amyloid beta-peptides and APO E in Down syndrome: implications 
for initial events in amyloid plaque formation. Neurobiol. Dis., 
1996, 3(1), 16-32. 
[16]  Goate, A.; Chartier-Harlin, M.C.; Mullan, M.; Brown, J.; Crawford, 
F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L.; Mant, 
R.; Newton, P.; Rooke, K.; Roques, P.; Talbot, C.; Pericak-Vance, 
M.; Roses, A.; Williamson, R.; Rossor, M.; Owen, M.; Hardy, J. 
Segregation of a missense mutation in the amyloid precursor   
protein gene with familial Alzheimer's disease. Nature,  1991, 
349(6311), 704-706. 
[17]  Chartier-Harlin, M.C.; Crawford, F.; Houlden, H.; Warren, A.; 
Hughes, D.; Fidani, L.; Goate, A.; Rossor, M.; Roques, P.; Hardy, 
J.; Mullan, M. Early-onset Alzheimer's disease caused by mutations 
at codon 717 of the beta-amyloid precursor protein gene. Nature, 
1991, 353(6347), 844-846. 
[18]  Murrell, J.; Farlow, M.; Ghetti, B.; Benson, M.D. A mutation in the 
amyloid precursor protein associated with hereditary Alzheimer's 
disease. Science, 1991, 254(5028), 97-99. 
[19]  Hendriks, L.; van Duijn, C.M.; Cras, P.; Cruts, M.; Van Hul, W.; 
van Harskamp, F.; Warren, A.; McInnis, M.G.; Antonarakis, S.E.; 
Martin, J.J.; Hofman, A.; van Broeckhoven, C. Presenile dementia 
and cerebral haemorrhage linked to a mutation at codon 692 of   
the beta-amyloid precursor protein gene. Nat Genet,  1992,  1(3), 
218-221. 
[20]  Rovelet-Lecrux, A.; Hannequin, D.; Raux, G.; Le Meur, N.; 
Laquerriere, A.; Vital, A.; Dumanchin, C.; Feuillette, S.; Brice, A.; 
Vercelletto, M.; Dubas, F.; Frebourg, T.; Campion, D. APP locus 
duplication causes autosomal dominant early-onset Alzheimer 
disease with cerebral amyloid angiopathy. Nat. Genet., 2006, 38(1), 
24-26. 
[21]  Mawuenyega, K.G.; Sigurdson, W.; Ovod, V.; Munsell, L.; Kasten, 
T.; Morris, J.C.; Yarasheski, K.E.; Bateman, R.J. Decreased 
clearance of CNS beta-amyloid in Alzheimer's disease. Science, 
2010, 330(6012), 1774. 
[22]  Hardy, J.A.; Higgins, G.A. Alzheimer's disease: the amyloid 
cascade hypothesis. Science, 1992, 256(5054), 184-185. 
[23]  Elder, G.A.; Gama Sosa, M.A.; De Gasperi, R. Transgenic mouse 
models of Alzheimer's disease. Mt Sinai J. Med., 2010, 77(1), 69-81. 
[24]  Gotz, J.; Ittner, L.M. Animal models of Alzheimer's disease and 
frontotemporal dementia. Nat. Rev. Neurosci., 2008, 9(7), 532-544. 
[25]  Albert, M.S.; Funkenstein, H.H. Disorders of the Nervous System. In: 
Nervous System, 2nd ed. Asburg, A.K., McKhanney, G.M., McDonald, 
W.I., Eds.; Saunders Inc.: Philadelphia; 1992, pp. 598-611. 
[26]  Petersen, R.C.; Smith, G.E.; Waring, S.C.; Ivnik, R.J.; Kokmen, E.; 
Tangelos, E.G. Aging, memory, and mild cognitive impairment. 
Int. Psychogeriatr., 1997, 9(Suppl 1), 65-69. 
[27]  Petersen, R.C.; Smith, G.E.; Waring, S.C.; Ivnik, R.J.; Tangalos, 
E.G.; Kokmen, E. Mild cognitive impairment: clinical characteriza- 
tion and outcome. Arch. Neurol., 1999, 56(3), 303-308. 
[28]  Joseph, J.; Cole, G.; Head, E.; Ingram, D. Nutrition, brain aging, 
and neurodegeneration. J. Neurosci., 2009, 29(41), 12795-12801. 
[29]  Zawia, N.H.; Lahiri, D.K.; Cardozo-Pelaez, F. Epigenetics, 
oxidative stress, and Alzheimer disease. Free Radic. Biol. Med., 
2009, 46(9), 1241-1249. 
[30]  Morris, J.C.; Storandt, M.; Miller, J.P.; McKeel, D.W.; Price, J.L.; 
Rubin, E.H.; Berg, L. Mild cognitive impairment represents early-
stage Alzheimer disease. Arch. Neurol., 2001, 58(3), 397-405. 
[31]  Knopman, D.S. The initial recognition and diagnosis of dementia. 
Am. J. Med., 1998, 104(4A), 2S-12S; discussion 39S-42S. 
[32]  Brizzee, K.R.; Ordy, J.M.; Hofer, H.; Kaack, B. Animal models for 
the study of brain disease and aging changes in teh brain. In: 
Alzheimer's disease: Senile dementia and related disorders, 
Katzman, R.; Terry, R.D.; Bick, K.L.; Eds.; Raven: New York; 
1978, pp. 515-554. 
[33]  Mosier, J.E. Effect of aging on body systems of the dog. Vet. Clin. 
North Am. Small Anim. Pract., 1989, 19(1), 1-12. 
[34]  Cummings, B.J.; Head, E.; Ruehl, W.; Milgram, N.W.; Cotman, 
C.W. The canine as an animal model of human aging and dementia. 
Neurobiol. Aging, 1996, 17(2), 259-268. 
[35]  Blizard, D.A.; Klein, L.C.; Cohen, R.; McClearn, G.E. A novel 
mouse-friendly cognitive task suitable for use in aging studies. 
Behav. Genet., 2003, 33(2), 181-189. 
[36]  Milgram, N.W.; Head, E.; Weiner, E.; Thomas, E. Cognitive 
functions and aging in the dog: acquisition of nonspatial visual 
tasks. Behav. Neurosci., 1994, 108(1), 57-68. 658    Current Neuropharmacology, 2011, Vol. 9, No. 4  Martin et al. 
[37]  Cotman, C.W.; Head, E. The canine (dog) model of human aging 
and disease: dietary, environmental and immunotherapy 
approaches. J. Alzheimers Dis., 2008, 15(4), 685-707. 
[38]  Adams, B.; Chan, A.; Callahan, H.; Milgram, N.W. The canine as a 
model of human cognitive aging: recent developments. Prog. 
Neuropsychopharmacol. Biol. Psychiatry, 2000, 24(5), 675-692. 
[39]  Head, E.; Mehta, R.; Hartley, J.; Kameka, M.; Cummings, B.J.; 
Cotman, C.W.; Ruehl, W.W.; Milgram, N.W. Spatial learning and 
memory as a function of age in the dog. Behav. Neurosci., 1995, 
109(5), 851-858. 
[40]  Rapp, P.R. Visual discrimination and reversal learning in the   
aged monkey (Macaca mulatta). Behav. Neurosci., 1990, 104(6), 
876-884. 
[41]  Rapp, P.R.; Amaral, D.G. Evidence for task-dependent memory 
dysfunction in the aged monkey. J. Neurosci., 1989, 9(10), 3568-
3576. 
[42]  Rapp, P.R.; Amaral, D.G. Recognition memory deficits in a 
subpopulation of aged monkeys resemble the effects of medial 
temporal lobe damage. Neurobiol. Aging, 1991, 12(5), 481-486. 
[43]  Walker, L.C.; Kitt, C.A.; Struble, R.G.; Wagster, M.V.; Price, D.L.; 
Cork, L.C. The neural basis of memory decline in aged monkeys. 
Neurobiol. Aging, 1988, 9(5-6), 657-666. 
[44]  Davis, R.T. Old monkey behavior. Exp. Gerontol., 1978, 13(3-4), 
237-250. 
[45]  Russell, M.J.; Bobik, M.; White, R.G.; Hou, Y.; Benjamin, S.A.; 
Geddes, J.W. Age-specific onset of beta-amyloid in beagle brains. 
Neurobiol. Aging, 1996, 17(2), 269-273. 
[46]  Bons, N.; Mestre, N.; Petter, A. Senile plaques and neurofibrillary 
changes in the brain of an aged lemurian primate, Microcebus 
murinus. Neurobiol. Aging, 1992, 13(1), 99-105. 
[47]  Selkoe, D.J.; Bell, D.S.; Podlisny, M.B.; Price, D.L.; Cork,   
L.C. Conservation of brain amyloid proteins in aged mammals   
and humans with Alzheimer's disease. Science, 1987, 235(4791), 
873-877. 
[48]  Cummings, B.J.; Head, E.; Afagh, A.J.; Milgram, N.W.; Cotman, 
C.W. Beta-amyloid accumulation correlates with cognitive 
dysfunction in the aged canine. Neurobiol. Learn Mem.,  1996, 
66(1), 11-23. 
[49]  Cummings, B.J.; Su, J.H.; Cotman, C.W.; White, R.; Russell, M.J. 
Beta-amyloid accumulation in aged canine brain: a model of early 
plaque formation in Alzheimer's disease. Neurobiol. Aging, 1993, 
14(6), 547-560. 
[50]  Head, E.; McCleary, R.; Hahn, F.F.; Milgram, N.W.; Cotman, 
C.W. Region-specific age at onset of beta-amyloid in dogs. 
Neurobiol. Aging, 2000, 21(1), 89-96. 
[51]  Head, E.; Torp, R. Insights into Abeta and presenilin from a canine 
model of human brain aging. Neurobiol. Dis., 2002, 9(1), 1-10. 
[52]  Giaccone, G.; Verga, L.; Finazzi, M.; Pollo, B.; Tagliavini, F.; 
Frangione, B.; Bugiani, O. Cerebral preamyloid deposits and 
congophilic angiopathy in aged dogs. Neurosci. Lett., 1990, 114(2), 
178-183. 
[53]  Morys, J.; Narkiewicz, O.; Maciejewska, B.; Wegiel, J.; 
Wisniewski, H.M. Amyloid deposits and loss of neurones in the 
claustrum of the aged dog. Neuroreport, 1994, 5(14), 1825-1828. 
[54]  Okuda, R.; Uchida, K.; Tateyama, S.; Yamaguchi, R.; Nakayama, 
H.; Goto, N. The distribution of amyloid beta precursor protein in 
canine brain. Acta Neuropathol., 1994, 87(2), 161-167. 
[55]  Russell, M.J.; White, R.; Patel, E.; Markesbery, W.R.; Watson, 
C.R.; Geddes, J.W. Familial influence on plaque formation in the 
beagle brain. Neuroreport, 1992, 3(12), 1093-1096. 
[56]  Uchida, K.; Tani, Y.; Uetsuka, K.; Nakayama, H.; Goto, N. 
Immunohistochemical studies on canine cerebral amyloid 
angiopathy and senile plaques. J. Vet. Med. Sci, 1992, 54(4),  
659-667. 
[57]  Markesbery, W.R.; Schmitt, F.A.; Kryscio, R.J.; Davis, D.G.; 
Smith, C.D.; Wekstein, D.R. Neuropathologic substrate of mild 
cognitive impairment. Arch. Neurol., 2006, 63(1), 38-46. 
[58]  Morris, J.C.; Storandt, M.; McKeel, D.W., Jr.; Rubin, E.H.; Price, 
J.L.; Grant, E.A.; Berg, L. Cerebral amyloid deposition and diffuse 
plaques in "normal" aging: Evidence for presymptomatic and very 
mild Alzheimer's disease. Neurology, 1996, 46(3), 707-719. 
[59]  Ishihara, T.; Gondo, T.; Takahashi, M.; Uchino, F.; Ikeda, S.; 
Allsop, D.; Imai, K. Immunohistochemical and immunoelectron 
microscopical characterization of cerebrovascular and senile plaque 
amyloid in aged dogs' brains. Brain Res., 1991, 548(1-2), 196-205. 
[60]  Thal, D.R.; Rub, U.; Orantes, M.; Braak, H. Phases of A beta-
deposition in the human brain and its relevance for the 
development of AD. Neurology, 2002, 58(12), 1791-1800. 
[61]  Wisniewski, H.; Johnson, A.B.; Raine, C.S.; Kay, W.J.; Terry, R.D. 
Senile plaques and cerebral amyloidosis in aged dogs. A 
histochemical and ultrastructural study. Lab. Invest., 1970, 23(3), 
287-296. 
[62]  Attems, J. Sporadic cerebral amyloid angiopathy: pathology, 
clinical implications, and possible pathomechanisms. Acta 
Neuropathol., 2005, 110(4), 345-359. 
[63]  Attems, J.; Jellinger, K.A.; Lintner, F. Alzheimer's disease 
pathology influences severity and topographical distribution of 
cerebral amyloid angiopathy. Acta Neuropathol.,  2005,  110(3), 
222-231. 
[64]  Herzig, M.C.; Van Nostrand, W.E.; Jucker, M. Mechanism of 
cerebral beta-amyloid angiopathy: murine and cellular models. 
Brain Pathol., 2006, 16(1), 40-54. 
[65]  Prior, R.; D'Urso, D.; Frank, R.; Prikulis, I.; Pavlakovic, G. Loss of 
vessel wall viability in cerebral amyloid angiopathy. Neuroreport, 
1996, 7(2), 562-564. 
[66]  Tian, J.; Shi, J.; Mann, D.M. Cerebral amyloid angiopathy and 
dementia. Panminerva Med., 2004, 46(4), 253-264. 
[67]  Uchida, K.; Nakayama, H.; Goto, N. Pathological studies on 
cerebral amyloid angiopathy, senile plaques and amyloid 
deposition in visceral organs in aged dogs. J. Vet. Med. Sci., 1991, 
53(6), 1037-1042. 
[68]  Selkoe, D.J. Soluble oligomers of the amyloid beta-protein impair 
synaptic plasticity and behavior. Behav. Brain Res., 2008, 192(1), 
106-113. 
[69]  Tomic, J.L.; Pensalfini, A.; Head, E.; Glabe, C.G. Soluble fibrillar 
oligomer levels are elevated in Alzheimer's disease brain and 
correlate with cognitive dysfunction. Neurobiol. Dis., 2009, 35(3), 
352-358. 
[70]  Mc Donald, J.M.; Savva, G.M.; Brayne, C.; Welzel, A.T.; Forster, 
G.; Shankar, G.M.; Selkoe, D.J.; Ince, P.G.; Walsh, D.M. The 
presence of sodium dodecyl sulphate-stable Abeta dimers is 
strongly associated with Alzheimer-type dementia. Brain,  2010, 
133(Pt 5), 1328-1341. 
[71]  Pop, V.; Head, E.; Berchtold, N.C.; Glabe, C.G.; Studzinski, C.M.; 
Weidner, A.M.; Murphy, M.P.; Cotman, C.W. Abeta aggregation 
profiles and shifts in APP processing favor amyloidogenesis in 
canines. Neurobiol. Aging,  2010 [Epub a head of print]. doi:10. 
1016/j.neurobiolaging.2010.02.008 
[72]  Pugliese, M.; Gangitano, C.; Ceccariglia, S.; Carrasco, J.L.; Del Fa, 
A.; Rodriguez, M.J.; Michetti, F.; Mascort, J.; Mahy, N. Canine 
cognitive dysfunction and the cerebellum: acetylcholinesterase 
reduction, neuronal and glial changes. Brain Res.,  2007,  1139,  
85-94. 
[73]  Dringenberg, H.C. Alzheimer's disease: more than a 'cholinergic 
disorder' - evidence that cholinergic-monoaminergic interactions 
contribute to EEG slowing and dementia. Behav. Brain Res., 2000, 
115(2), 235-249. 
[74]  Grudzien, A.; Shaw, P.; Weintraub, S.; Bigio, E.; Mash, D.C.; 
Mesulam, M.M. Locus coeruleus neurofibrillary degeneration in 
aging, mild cognitive impairment and early Alzheimer's disease. 
Neurobiol. Aging, 2007, 28(3), 327-335. 
[75]  Insua, D.; Suarez, M.L.; Santamarina, G.; Sarasa, M.; Pesini, P. 
Dogs with canine counterpart of Alzheimer's disease lose 
noradrenergic neurons. Neurobiol. Aging, 2010, 31(4), 625-635. 
[76]  Wegiel, J.; Kuchna, I.; Nowicki, K.; Frackowiak, J.; Mazur-
Kolecka, B.; Imaki, H.; Mehta, P.D.; Silverman, W.P.; Reisberg, 
B.; Deleon, M.; Wisniewski, T.; Pirttilla, T.; Frey, H.; Lehtimaki, 
T.; Kivimaki, T.; Visser, F.E.; Kamphorst, W.; Potempska,   
A.; Bolton, D.; Currie, J.R.; Miller, D.L. Intraneuronal Abeta 
immunoreactivity is not a predictor of brain amyloidosis-beta   
or neurofibrillary degeneration. Acta Neuropathol., 2007, 113(4), 
389-402. 
[77]  Hartley, D.M.; Walsh, D.M.; Ye, C.P.; Diehl, T.; Vasquez, S.; 
Vassilev, P.M.; Teplow, D.B.; Selkoe, D.J. Protofibrillar 
intermediates of amyloid beta-protein induce acute electro- 
physiological changes and progressive neurotoxicity in cortical 
neurons. J. Neurosci., 1999, 19(20), 8876-8884. 
[78]  Walsh, D.M.; Hartley, D.M.; Kusumoto, Y.; Fezoui, Y.; Condron, 
M.M.; Lomakin, A.; Benedek, G.B.; Selkoe, D.J.; Teplow, D.B. 
Amyloid beta-protein fibrillogenesis. Structure and biological Therapeutic Interventions Targeting Beta Amyloid Pathogenesis  Current Neuropharmacology, 2011, Vol. 9, No. 4    659 
activity of protofibrillar intermediates. J. Biol. Chem.,  1999, 
274(36), 25945-25952. 
[79]  Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, 
R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, 
K.L.; Wals, P.; Zhang, C.; Finch, C.E.; Krafft, G.A.; Klein, W.L. 
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent 
central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A., 
1998, 95(11), 6448-6453. 
[80]  Lesne, S.; Koh, M.T.; Kotilinek, L.; Kayed, R.; Glabe, C.G.; Yang, 
A.; Gallagher, M.; Ashe, K.H. A specific amyloid-beta protein 
assembly in the brain impairs memory. Nature, 2006, 440(7082), 
352-357. 
[81]  Roher, A.E.; Chaney, M.O.; Kuo, Y.M.; Webster, S.D.; Stine, 
W.B.; Haverkamp, L.J.; Woods, A.S.; Cotter, R.J.; Tuohy, J.M.; 
Krafft, G.A.; Bonnell, B.S.; Emmerling, M.R. Morphology and 
toxicity of Abeta-(1-42) dimer derived from neuritic and vascular 
amyloid deposits of Alzheimer's disease. J. Biol. Chem.,  1996, 
271(34), 20631-20635. 
[82]  LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-beta in 
Alzheimer's disease. Nat. Rev. Neurosci., 2007, 8(7), 499-509. 
[83]  Middleton, L.E.; Yaffe, K. Promising strategies for the prevention 
of dementia. Arch. Neurol., 2009, 66(10), 1210-1215. 
[84]  Lee, J.W.; Lee, Y.K.; Ban, J.O.; Ha, T.Y.; Yun, Y.P.; Han, S.B.; 
Oh, K.W.; Hong, J.T. Green tea (-)-epigallocatechin-3-gallate 
inhibits beta-amyloid-induced cognitive dysfunction through 
modification of secretase activity via inhibition of ERK and NF-
kappaB pathways in mice. J. Nutr., 2009, 139(10), 1987-1993. 
[85]  Lim, G.P.; Calon, F.; Morihara, T.; Yang, F.; Teter, B.; Ubeda, O.; 
Salem, N., Jr.; Frautschy, S.A.; Cole, G.M. A diet enriched with the 
omega-3 fatty acid docosahexaenoic acid reduces amyloid burden 
in an aged Alzheimer mouse model. J. Neurosci., 2005, 25(12), 
3032-3040. 
[86]  Lazarov, O.; Robinson, J.; Tang, Y.P.; Hairston, I.S.; Korade-
Mirnics, Z.; Lee, V.M.; Hersh, L.B.; Sapolsky, R.M.; Mirnics,   
K.; Sisodia, S.S. Environmental enrichment reduces Abeta   
levels and amyloid deposition in transgenic mice. Cell,  2005, 
120(5), 701-713. 
[87]  Churchill, J.D.; Galvez, R.; Colcombe, S.; Swain, R.A.; Kramer, 
A.F.; Greenough, W.T. Exercise, experience and the aging brain. 
Neurobiol. Aging, 2002, 23(5), 941-955. 
[88]  Cotman, C.W.; Berchtold, N.C. Exercise: a behavioral intervention 
to enhance brain health and plasticity. Trends Neurosci., 2002, 
25(6), 295-301. 
[89]  Engelhart, M.J.; Geerlings, M.I.; Ruitenberg, A.; van Swieten, J.C.; 
Hofman, A.; Witteman, J.C.; Breteler, M.M. Dietary intake of 
antioxidants and risk of Alzheimer disease. JAMA, 2002, 287(24), 
3223-3229. 
[90]  Morris, M.C.; Evans, D.A.; Bienias, J.L.; Tangney, C.C.; Wilson, 
R.S. Vitamin E and cognitive decline in older persons. Arch. 
Neurol., 2002, 59(7), 1125-1132. 
[91]  Erickson, K.I.; Kramer, A.F. Aerobic exercise effects on cognitive 
and neural plasticity in older adults. Br. J. Sports Med., 2009, 
43(1), 22-24. 
[92]  Willis, S.L.; Tennstedt, S.L.; Marsiske, M.; Ball, K.; Elias, J.; 
Koepke, K.M.; Morris, J.N.; Rebok, G.W.; Unverzagt, F.W.; 
Stoddard, A.M.; Wright, E. Long-term effects of cognitive training 
on everyday functional outcomes in older adults. JAMA,  2006, 
296(23), 2805-2814. 
[93]  Ball, K.; Berch, D.B.; Helmers, K.F.; Jobe, J.B.; Leveck, M.D.; 
Marsiske, M.; Morris, J.N.; Rebok, G.W.; Smith, D.M.; Tennstedt, 
S.L.; Unverzagt, F.W.; Willis, S.L. Effects of cognitive training 
interventions with older adults: a randomized controlled trial. 
JAMA, 2002, 288(18), 2271-2281. 
[94]  Milgram, N.W.; Zicker, S.C.; Head, E.; Muggenburg, B.A.; 
Murphey, H.; Ikeda-Douglas, C.J.; Cotman, C.W. Dietary 
enrichment counteracts age-associated cognitive dysfunction in 
canines. Neurobiol. Aging, 2002, 23(5), 737-745. 
[95]  Milgram, N.W.; Head, E.; Zicker, S.C.; Ikeda-Douglas, C.J.; 
Murphey, H.; Muggenburg, B.; Siwak, C.; Tapp, D.; Cotman, C.W. 
Learning ability in aged beagle dogs is preserved by behavioral 
enrichment and dietary fortification: a two-year longitudinal study. 
Neurobiol. Aging, 2005, 26(1), 77-90. 
[96]  Pop, V.; Head, E.; Berchtold, N.C.; Glabe, C.; Studzinski, C.M.; 
Weidner, A.M.; Murphy, M.P.; Cotman, C.W. Beta-amyloid 
aggregation profiles and shifts in APP processing favor 
amyloidogenesis in canines. Neurobiol. Aging, 2010. doi:10.1016/ 
j.neurobiolaging.2010.02.008 
[97]  Fukumoto, H.; Cheung, B.S.; Hyman, B.T.; Irizarry, M.C. Beta-
secretase protein and activity are increased in the neocortex in 
Alzheimer disease. Arch Neurol, 2002, 59(9), 1381-1389. 
[98]  Yang, L.B.; Lindholm, K.; Yan, R.; Citron, M.; Xia, W.; Yang, 
X.L.; Beach, T.; Sue, L.; Wong, P.; Price, D.; Li, R.; Shen, Y. 
Elevated beta-secretase expression and enzymatic activity detected 
in sporadic Alzheimer disease. Nat. Med., 2003, 9(1), 3-4. 
[99]  Li, R.; Lindholm, K.; Yang, L.B.; Yue, X.; Citron, M.; Yan, R.; 
Beach, T.; Sue, L.; Sabbagh, M.; Cai, H.; Wong, P.; Price, D.; 
Shen, Y. Amyloid beta peptide load is correlated with increased 
beta-secretase activity in sporadic Alzheimer's disease patients. 
Proc. Natl. Acad. Sci. U. S. A., 2004, 101(10), 3632-3637. 
[100]  Vassar, R.; Kovacs, D.M.; Yan, R.; Wong, P.C. The beta-secretase 
enzyme BACE in health and Alzheimer's disease: regulation, cell 
biology, function, and therapeutic potential. J. Neurosci.,  2009, 
29(41), 12787-12794. 
[101]  Stefansson, H.; Sigurdsson, E.; Steinthorsdottir, V.; Bjornsdottir, 
S.; Sigmundsson, T.; Ghosh, S.; Brynjolfsson, J.; Gunnarsdottir, S.; 
Ivarsson, O.; Chou, T.T.; Hjaltason, O.; Birgisdottir, B.; Jonsson, 
H.; Gudnadottir, V.G.; Gudmundsdottir, E.; Bjornsson, A.; 
Ingvarsson, B.; Ingason, A.; Sigfusson, S.; Hardardottir, H.; 
Harvey, R.P.; Lai, D.; Zhou, M.; Brunner, D.; Mutel, V.; Gonzalo, 
A.; Lemke, G.; Sainz, J.; Johannesson, G.; Andresson, T.; 
Gudbjartsson, D.; Manolescu, A.; Frigge, M.L.; Gurney, M.E.; 
Kong, A.; Gulcher, J.R.; Petursson, H.; Stefansson, K. Neuregulin 
1 and susceptibility to schizophrenia. Am. J. Hum. Genet., 2002, 
71(4), 877-892. 
[102]  Gerlai, R.; Pisacane, P.; Erickson, S. Heregulin, but not ErbB2 or 
ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple 
behavioral tasks. Behav. Brain Res., 2000, 109(2), 219-227. 
[103]  McConlogue, L.; Buttini, M.; Anderson, J.P.; Brigham, E.F.; Chen, 
K.S.; Freedman, S.B.; Games, D.; Johnson-Wood, K.; Lee, M.; 
Zeller, M.; Liu, W.; Motter, R.; Sinha, S. Partial reduction of 
BACE1 has dramatic effects on Alzheimer plaque and synaptic 
pathology in APP Transgenic Mice. J. Biol. Chem., 2007, 282(36), 
26326-26334. 
[104]  Jick, H.; Zornberg, G.L.; Jick, S.S.; Seshadri, S.; Drachman,   
D.A. Statins and the risk of dementia. Lancet, 2000, 356(9242), 
1627-1631. 
[105]  Wolozin, B.; Kellman, W.; Ruosseau, P.; Celesia, G.G.; Siegel, G. 
Decreased prevalence of Alzheimer disease associated with 3-
hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. 
Neurol., 2000, 57(10), 1439-1443. 
[106]  Rockwood, K.; Kirkland, S.; Hogan, D.B.; MacKnight, C.; Merry, 
H.; Verreault, R.; Wolfson, C.; McDowell, I. Use of lipid-lowering 
agents, indication bias, and the risk of dementia in community-
dwelling elderly people. Arch. Neurol., 2002, 59(2), 223-227. 
[107]  Hajjar, I.; Schumpert, J.; Hirth, V.; Wieland, D.; Eleazer, G.P. The 
impact of the use of statins on the prevalence of dementia and the 
progression of cognitive impairment. J. Gerontol. A Biol. Sci. Med. 
Sci., 2002, 57(7), M414-418. 
[108]  Rodriguez, E.G.; Dodge, H.H.; Birzescu, M.A.; Stoehr, G.P.; 
Ganguli, M. Use of lipid-lowering drugs in older adults with and 
without dementia: a community-based epidemiological study. J. 
Am. Geriatr. Soc., 2002, 50(11), 1852-1856. 
[109]  Dufouil, C.; Richard, F.; Fievet, N.; Dartigues, J.F.; Ritchie, K.; 
Tzourio, C.; Amouyel, P.; Alperovitch, A. APOE genotype, 
cholesterol level, lipid-lowering treatment, and dementia: the 
Three-City Study. Neurology, 2005, 64(9), 1531-1538. 
[110]  Zamrini, E.; McGwin, G.; Roseman, J.M. Association between 
statin use and Alzheimer's disease. Neuroepidemiology, 2004, 23(1-
2), 94-98. 
[111]  Wolozin, B.; Wang, S.W.; Li, N.C.; Lee, A.; Lee, T.A.; Kazis, L.E. 
Simvastatin is associated with a reduced incidence of dementia and 
Parkinson's disease. BMC Med, 2007, 5, 20. 
[112]  Li, G.; Higdon, R.; Kukull, W.A.; Peskind, E.; Van Valen Moore, 
K.; Tsuang, D.; van Belle, G.; McCormick, W.; Bowen, J.D.; Teri, 
L.; Schellenberg, G.D.; Larson, E.B. Statin therapy and risk of 
dementia in the elderly: a community-based prospective cohort 
study. Neurology, 2004, 63(9), 1624-1628. 
[113]  Rea, T.D.; Breitner, J.C.; Psaty, B.M.; Fitzpatrick, A.L.; Lopez, 
O.L.; Newman, A.B.; Hazzard, W.R.; Zandi, P.P.; Burke, G.L.; 
Lyketsos, C.G.; Bernick, C.; Kuller, L.H. Statin use and the risk of 660    Current Neuropharmacology, 2011, Vol. 9, No. 4  Martin et al. 
incident dementia: the Cardiovascular Health Study. Arch. Neurol., 
2005, 62(7), 1047-1051. 
[114]  Zandi, P.P.; Sparks, D.L.; Khachaturian, A.S.; Tschanz, J.; Norton, 
M.; Steinberg, M.; Welsh-Bohmer, K.A.; Breitner, J.C. Do statins 
reduce risk of incident dementia and Alzheimer disease? The 
Cache County Study. Arch. Gen. Psychiatry, 2005, 62(2), 217-224. 
[115]  Haag, M.D.; Hofman, A.; Koudstaal, P.J.; Stricker, B.H.; Breteler, 
M.M. Statins are associated with a reduced risk of Alzheimer 
disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. 
Neurosurg. Psychiatry, 2009, 80(1), 13-17. 
[116]  Rockwood, K. Epidemiological and clinical trials evidence about a 
preventive role for statins in Alzheimer's disease. Acta Neurol. 
Scand Suppl., 2006, 185, 71-77. 
[117]  Sparks, L. Statins and cognitive function. J. Neurol. Neurosurg. 
Psychiatry, 2009, 80(1), 1-2. 
[118]  Simons, M.; Schwarzler, F.; Lutjohann, D.; von Bergmann, K.; 
Beyreuther, K.; Dichgans, J.; Wormstall, H.; Hartmann, T.; Schulz, 
J.B. Treatment with simvastatin in normocholesterolemic patients 
with Alzheimer's disease: A 26-week randomized, placebo-
controlled, double-blind trial. Ann. Neurol., 2002, 52(3), 346-350. 
[119]  Sparks, D.L.; Connor, D.J.; Sabbagh, M.N.; Petersen, R.B.; Lopez, 
J.; Browne, P. Circulating cholesterol levels, apolipoprotein E 
genotype and dementia severity influence the benefit of atorvastatin 
treatment in Alzheimer's disease: results of the Alzheimer's Disease 
Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol. 
Scand Suppl, 2006, 185, 3-7. 
[120]  Sparks, D.L.; Sabbagh, M.N.; Connor, D.J.; Lopez, J.; Launer, L.J.; 
Petanceska, S.; Browne, P.; Wassar, D.; Johnson-Traver, S.; 
Lochhead, J.; Ziolkowski, C. Atorvastatin therapy lowers 
circulating cholesterol but not free radical activity in advance of 
identifiable clinical benefit in the treatment of mild-to-moderate 
AD. Curr. Alzheimer Res., 2005, 2(3), 343-353. 
[121]  Sparks, D.L.; Sabbagh, M.N.; Connor, D.J.; Lopez, J.; Launer, L.J.; 
Browne, P.; Wasser, D.; Johnson-Traver, S.; Lochhead, J.; 
Ziolwolski, C. Atorvastatin for the treatment of mild to moderate 
Alzheimer disease: preliminary results. Arch. Neurol., 2005, 62(5), 
753-757. 
[122]  Sparks, D.L.; Sabbagh, M.; Connor, D.; Soares, H.; Lopez, J.; 
Stankovic, G.; Johnson-Traver, S.; Ziolkowski, C.; Browne, P. 
Statin therapy in Alzheimer's disease. Acta Neurol. Scand. Suppl, 
2006, 185, 78-86. 
[123]  Pappolla, M.A. Statins, incident Alzheimer disease, change in 
cognitive function, and neuropathology. Neurology, 2008, 71(24), 
2020; author reply 2020-2021. 
[124]  Solomon, A.; Kareholt, I.; Ngandu, T.; Wolozin, B.; Macdonald, 
S.W.; Winblad, B.; Nissinen, A.; Tuomilehto, J.; Soininen, H.; 
Kivipelto, M. Serum total cholesterol, statins and cognition in non-
demented elderly. Neurobiol. Aging, 2009, 30(6), 1006-1009. 
[125]  Cramer, C.; Haan, M.N.; Galea, S.; Langa, K.M.; Kalbfleisch, J.D. 
Use of statins and incidence of dementia and cognitive impairment 
without dementia in a cohort study. Neurology, 2008, 71(5), 344-
350. 
[126]  Simons, M.; Keller, P.; Strooper, B.D.; Beyreuther, K.; Dotti, C.G.; 
Simons, K. Cholesterol depletion inhibits the generation of beta-
amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA, 1998, 
95, 6460-6464. 
[127]  Hartmann, T. Cholesterol, A beta and Alzheimer's disease. Trends 
Neurosci., 2001, 24(11 Suppl), S45-48. 
[128]  Petanceska, S.S.; DeRosa, S.; Olm, V.; Diaz, N.; Sharma, A.; 
Thomas-Bryant, T.; Duff, K.; Pappolla, M.; Refolo, L.M. Statin 
therapy for Alzheimer's disease: will it work? J. Mol. Neurosci., 
2002, 19(1-2), 155-161. 
[129]  Alberts, A.W. Lovastatin and simvastatin - inhibitors of HMG CoA 
reductase and cholesterol biosynthesis. Cardiology,  1990, 77(4), 
14-21. 
[130]  Fears, R.; Richards, D.H.; Ferres, H. The effect of compactin, a 
potent inhibitor of 3-hydroxy-3-methylgutaryl co-enzyme-A 
reductase activity, on cholesterogenesis and serum cholesterol 
levels in rats and chicks. Atherosclerosis, 1980, 35(4), 439-449. 
[131]  Todd, P.A.; Goa, K.L. Simvastatin.  A review of its pharma- 
cological properties and therapeutic potential in hyper- 
cholesterolaemia. Drugs, 1990, 40(4), 583-607. 
[132]  Thelen, K.M.; Rentsch, K.M.; Gutteck, U.; Heverin, M.; Olin, M.; 
Andersson, U.; von Eckardstein, A.; Bjorkhem, I.; Lutjohann, D. 
Brain cholesterol synthesis in mice is affected by high dose of 
simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther., 2006, 
316(3), 1146-1152. 
[133]  Gerson, R.J.; MacDonald, J.S.; Alberts, A.W.; Kornbrust, D.J.; 
Majka, J.A.; Stubbs, R.J.; Bokelman, D.L. Animal safety and 
toxicology of simvastatin and related hydroxy-methylglutaryl-
coenzyme A reductase inhibitors. Am. J. Med., 1989, 87(4A), 28S-
38S. 
[134]  Bush, A.I.; Pettingell, W.H.; Multhaup, G.; d Paradis, M.; 
Vonsattel, J.P.; Gusella, J.F.; Beyreuther, K.; Masters, C.L.; Tanzi, 
R.E. Rapid induction of Alzheimer A beta amyloid formation by 
zinc. Science, 1994, 265(5177), 1464-1467. 
[135]  Bush, A.I.; Pettingell, W.H., Jr.; Paradis, M.D.; Tanzi, R.E. 
Modulation of A beta adhesiveness and secretase site cleavage by 
zinc. J. Biol. Chem., 1994, 269(16), 12152-12158. 
[136]  Ha, C.; Ryu, J.; Park, C.B. Metal ions differentially influence the 
aggregation and deposition of Alzheimer's beta-amyloid on a solid 
template. Biochemistry, 2007, 46(20), 6118-6125. 
[137]  Noy, D.; Solomonov, I.; Sinkevich, O.; Arad, T.; Kjaer, K.; Sagi, I. 
Zinc-amyloid beta interactions on a millisecond time-scale stabilize 
non-fibrillar Alzheimer-related species. J. Am. Chem. Soc., 2008, 
130(4), 1376-1383. 
[138]  Sensi, S.L.; Paoletti, P.; Bush, A.I.; Sekler, I. Zinc in the 
physiology and pathology of the CNS. Nat. Rev. Neurosci., 2009, 
10(11), 780-791. 
[139]  Grundke-Iqbal, I.; Fleming, J.; Tung, Y.C.; Lassmann, H.; Iqbal, 
K.; Joshi, J.G. Ferritin is a component of the neuritic (senile) 
plaque in Alzheimer dementia. Acta Neuropathol.,  1990,  81(2), 
105-110. 
[140]  Quinn, J.F.; Crane, S.; Harris, C.; Wadsworth, T.L. Copper in 
Alzheimer's disease: too much or too little? Expert Rev. Neurother., 
2009, 9(5), 631-637. 
[141]  Cherny, R.A.; Atwood, C.S.; Xilinas, M.E.; Gray, D.N.; Jones, 
W.D.; McLean, C.A.; Barnham, K.J.; Volitakis, I.; Fraser, F.W.; 
Kim, Y.; Huang, X.; Goldstein, L.E.; Moir, R.D.; Lim, J.T.; 
Beyreuther, K.; Zheng, H.; Tanzi, R.E.; Masters, C.L.; Bush, A.I. 
Treatment with a copper-zinc chelator markedly and rapidly 
inhibits beta-amyloid accumulation in Alzheimer's disease 
transgenic mice. Neuron, 2001, 30(3), 665-676. 
[142]  Adlard, P.A.; Cherny, R.A.; Finkelstein, D.I.; Gautier, E.; Robb, E.; 
Cortes, M.; Volitakis, I.; Liu, X.; Smith, J.P.; Perez, K.; Laughton, 
K.; Li, Q.X.; Charman, S.A.; Nicolazzo, J.A.; Wilkins, S.; Deleva, 
K.; Lynch, T.; Kok, G.; Ritchie, C.W.; Tanzi, R.E.; Cappai, R.; 
Masters, C.L.; Barnham, K.J.; Bush, A.I. Rapid restoration of 
cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline 
analogs is associated with decreased interstitial Abeta. Neuron, 
2008, 59(1), 43-55. 
[143]  Ritchie, C.W.; Bush, A.I.; Mackinnon, A.; Macfarlane, S.; 
Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q.X.; 
Tammer, A.; Carrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.; 
Ames, D.; Davis, S.; Beyreuther, K.; Tanzi, R.E.; Masters, C.L. 
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) 
targeting Abeta amyloid deposition and toxicity in Alzheimer 
disease: a pilot phase 2 clinical trial. Arch. Neurol., 2003, 60(12), 
1685-1691. 
[144]  Jenagaratnam, L.; McShane, R. Clioquinol for the treatment of 
Alzheimer's Disease. Cochrane Database Syst. Rev.,  2006, (1), 
CD005380. 
[145]  Sampson, E.; Jenagaratnam, L.; McShane, R. Metal protein 
attenuating compounds for the treatment of Alzheimer's disease. 
Cochrane Database Syst. Rev., 2008, (1), CD005380. 
[146]  Barden, H. The histochemical distribution and localization of 
copper, iron, neuromelanin and lysosomal enzyme activity in the 
brain of aging rhesus monkey and the dog. J. Neuropathol. Exp. 
Neurol., 1971, 30(4), 650-667. 
[147]  Das, P.; Howard, V.; Loosbrock, N.; Dickson, D.; Murphy, M.P.; 
Golde, T.E. Amyloid-beta immunization effectively reduces 
amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci., 
2003, 23(24), 8532-8538. 
[148]  Janus, C.; Pearson, J.; McLaurin, J.; Mathews, P.M.; Jiang, Y.; 
Schmidt, S.D.; Chishti, M.A.; Horne, P.; Heslin, D.; French, J.; 
Mount, H.T.; Nixon, R.A.; Mercken, M.; Bergeron, C.; Fraser, 
P.E.; St George-Hyslop, P.; Westaway, D. A beta peptide 
immunization reduces behavioural impairment and plaques in a 
model of Alzheimer's disease. Nature, 2000, 408(6815), 979-982. Therapeutic Interventions Targeting Beta Amyloid Pathogenesis  Current Neuropharmacology, 2011, Vol. 9, No. 4    661 
[149]  Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, 
C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; 
Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. A 
beta peptide vaccination prevents memory loss in an animal model 
of Alzheimer's disease. Nature, 2000, 408(6815), 982-985. 
[150]  Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., 
Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., 
Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., 
Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandervert, C., 
Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. 
Immunization with amyloid- attentuates Alzheimer-disease-like 
pathology in the PDAPP mouse. Nature, 1999, 400, 173-177. 
[151]  Sigurdsson, E.M.; Knudsen, E.; Asuni, A.; Fitzer-Attas, C.; Sage, 
D.; Quartermain, D.; Goni, F.; Frangione, B.; Wisniewski, T. An 
attenuated immune response is sufficient to enhance cognition in an 
Alzheimer's disease mouse model immunized with amyloid-beta 
derivatives. J. Neurosci, 2004, 24(28), 6277-6282. 
[152]  Dodart, J.C.; Bales, K.R.; Gannon, K.S.; Greene, S.J.; DeMattos, 
R.B.; Mathis, C.; DeLong, C.A.; Wu, S.; Wu, X.; Holtzman, D.M.; 
Paul, S.M. Immunization reverses memory deficits without 
reducing brain Abeta burden in Alzheimer's disease model. Nat. 
Neurosci., 2002, 5(5), 452-457. 
[153]  Kotilinek, L.A.; Bacskai, B.; Westerman, M.; Kawarabayashi, T.; 
Younkin, L.; Hyman, B.T.; Younkin, S.; Ashe, K.H. Reversible 
memory loss in a mouse transgenic model of Alzheimer's disease. 
J. Neurosci., 2002, 22(15), 6331-6335. 
[154]  Morley, J.E.; Farr, S.A.; Flood, J.F. Antibody to amyloid beta 
protein alleviates impaired acquisition, retention, and memory 
processing in SAMP8 mice. Neurobiol. Learn Mem., 2002, 78(1), 
125-138. 
[155]  Wilcock, D.M.; Rojiani, A.; Rosenthal, A.; Levkowitz, G.; 
Subbarao, S.; Alamed, J.; Wilson, D.; Wilson, N.; Freeman, M.J.; 
Gordon, M.N.; Morgan, D. Passive amyloid immunotherapy clears 
amyloid and transiently activates microglia in a transgenic mouse 
model of amyloid deposition. J. Neurosci.,  2004,  24(27), 6144-
6151. 
[156]  Head, E.; Pop, V.; Vasilevko, V.; Hill, M.; Saing, T.; Sarsoza, F.; 
Nistor, M.; Christie, L.A.; Milton, S.; Glabe, C.; Barrett, E.; Cribbs, 
D. A two-year study with fibrillar beta-amyloid (Abeta) 
immunization in aged canines: effects on cognitive function and 
brain Abeta. J. Neurosci., 2008, 28(14), 3555-3566. 
[157]  Orgogozo, J.M.; Gilman, S.; Dartigues, J.F.; Laurent, B.; Puel, M.; 
Kirby, L.C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; 
Michel, B.F.; Boada, M.; Frank, A.; Hock, C. Subacute 
meningoencephalitis in a subset of patients with AD after Abeta42 
immunization. Neurology, 2003, 61(1), 46-54. 
[158]  Hock, C.; Konietzko, U.; Streffer, J.R.; Tracy, J.; Signorell, A.; 
Muller-Tillmanns, B.; Lemke, U.; Henke, K.; Moritz, E.; Garcia, 
E.; Wollmer, M.A.; Umbricht, D.; de Quervain, D.J.; Hofmann, M.; 
Maddalena, A.; Papassotiropoulos, A.; Nitsch, R.M. Antibodies 
against beta-amyloid slow cognitive decline in Alzheimer's disease. 
Neuron, 2003, 38(4), 547-554. 
[159]  Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; 
Fox, N.C.; Eisner, L.; Kirby, L.; Rovira, M.B.; Forette, F.; 
Orgogozo, J.M. Clinical effects of Abeta immunization (AN1792) 
in patients with AD in an interrupted trial. Neurology, 2005, 64(9), 
1553-1562. 
[160]  Ferrer, I.; Boada Rovira, M.; Sanchez Guerra, M.L.; Rey, M.J.; 
Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis 
following amyloid-beta immunization in Alzheimer's disease. 
Brain Pathol., 2004, 14(1), 11-20. 
[161]  Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; 
Weller, R.O. Neuropathology of human Alzheimer disease after 
immunization with amyloid-beta peptide: a case report. Nat. Med., 
2003, 9(4), 448-452. 
[162]  Masliah, E.; Hansen, L.; Adame, A.; Crews, L.; Bard, F.; Lee, C.; 
Seubert, P.; Games, D.; Kirby, L.; Schenk, D. Abeta vaccination 
effects on plaque pathology in the absence of encephalitis in 
Alzheimer disease. Neurology, 2005, 64(1), 129-131. 
[163]  Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, 
V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; 
Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 
immunisation in Alzheimer's disease: follow-up of a randomised, 
placebo-controlled phase I trial. Lancet, 2008, 372(9634), 216-223. 
[164]  Lai, Z.C.; Moss, M.B.; Killiany, R.J.; Rosene, D.L.; Herndon, J.G. 
Executive system dysfunction in the aged monkey:  spatial and 
object reversal learning. Neurobiol. Aging, 1995, 16, 947-954. 
[165]  Cronin-Golomb, A. Color vision, object recognition, and spatial 
localization in aging and Alzheimer's disease. In: Functional 
Neurobiology of Aging, Hof, P.R., Mobbs, C.V., Eds.; Academic 
Press: San Diego; 2001, pp. 517-529. 
[166]  Boutet, I.; Milgram, N.W.; Freedman, M. Cognitive decline and 
human (Homo sapiens) aging: an investigation using a comparative 
neuropsychological approach. J. Comp. Psychol.,  2007,  121(3), 
270-281. 
[167]  Freedman, M.; Oscar-Berman, M. Spatial and visual learning 
deficits in Alzheimer's disease and Parkinson's disease. Brain 
Cognit., 1989, 11, 114-126. 
[168]  Emborg, M.E.; Ma, S.Y.; Mufson, E.J.; Levey, A.I.; Taylor, M.D.; 
Brown, W.D.; Holden, J.E.; Kordower, J.H. Age-related declines in 
nigral neuronal function correlate with motor impairments in rhesus 
monkeys. J. Comp. Neurol., 1998, 401(2), 253-265. 
[169]  Kordower, J.H.; Liu, Y.T.; Winn, S.; Emerich, D.F. Encapsulated 
PC12 cell transplants into hemiparkinsonian monkeys: a 
behavioral, neuroanatomical, and neurochemical analysis. Cell 
Transplant., 1995, 4(2), 155-171. 
[170]  Christie, L.A.; Studzinski, C.M.; Araujo, J.A.; Leung, C.S.; Ikeda-
Douglas, C.J.; Head, E.; Cotman, C.W.; Milgram, N.W. A 
comparison of egocentric and allocentric age-dependent spatial 
learning in the beagle dog. Prog. Neuropsychopharmacol. Biol. 
Psychiatry, 2005, 29(3), 361-369. 
[171]  Mishkin, M.; Delacour, J. An analysis of short-term visual memory 
in the monkey. J. Exper. Psychol:  Anim. Behav. Proc., 1975, 1, 
326-334. 
[172]  Lezak, M.D.; Howieson, D.B.; Loring, D.W. Neuropsychological 
Assessment. Oxford University Press: New York,2004. 
[173]  Arnsten, A.F.T., and Goldman-Rakic, P.S. Alpha 2-adrenergic 
mechanisms in prefrontal cortex associated with cognitive decline 
in aged nonhuman primates. Science, 1985, 230, 1273-1276. 
[174]  Kowalska, D.M. Effects of hippocampal lesions on spatial delayed 
responses in dog. Hippocampus, 1995, 5(4), 363-370. 
[175]  Warren, J.M. The behavior of carnivores and primates with lesions 
in the prefrontal cortex. In: The Frontal Granular Cortex and 
Behavior, Warren, J.M., Akert, K., Eds.; McGraw-Hill Book 
Company: New York; 1964, pp. 168-191. 
[176]  Kramer, J.H.; Quitania, L. Bedside Frontal Lobe Testing. In: The 
Human Frontal Lobes, Miller, B.L., Cummings, J.L., Ed.; The 
Guilford Press: New York; 2007, pp. 279-291. 
[177]  Rapp, P.R.; Kansky, M.T.; Eichenbaum, H. Learning and memory 
for hierarchical relationships in the monkey: effects of aging. 
Behav. Neurosci., 1996, 110(5), 887-897. 
[178]  Pohl, W. Dissociation of spatial discrimination deficits following 
frontal and parietal lesions in monkeys. J. Comp. Physiol. Psychol., 
1973, 82, 227-239. 
 
 
Received: March 05, 2010  Revised: December 15, 2010  Accepted: January 13, 2011 
 
 